INDICATIONS AND USAGE（适应症）

BOSULIF is indicated for the treatment of adult patients with:

Newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).

Chronic phase, accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy.

DOSAGE（服用剂量）

The recommended dose is taken orally once daily with food. The tablet is to be swallowed whole and should not be broken or cut. Continue treatment with BOSULIF until disease progression or intolerance to therapy.

If a dose is missed beyond 12 hours, the patient should skip the dose and take the usual prescribed dose on the following day.

Newly-Diagnosed CP Ph+ CML

The recommended dose of BOSULIF is 400 mg orally once daily with food.

CP, AP, or BP Ph+ CML with Resistance or Intolerance to Prior Therapy

The recommended dose and schedule of BOSULIF is 500 mg orally once daily with food.

ADVERSE REACTIONS（不良反应）

Gastrointestinal toxicity

Myelosuppression

Hepatic toxicity

Cardiovascular toxicity

Fluid retention

Renal toxicity

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/adc84ad5-a04d-4fee-9ba8-91f7abd928e3/spl-doc?hl=Bosutinib

Bosutinibinformation